Literature DB >> 834017

[Prophylaxis and therapy of shunt thrombosis in terminal renal insufficiency (author's transl)].

H Köhler.   

Abstract

In terminal renal insufficiency thrombosis occurs almost exclusively in the arteriovenous shunt. The management of this acute, life threatening thrombosis is hardly contested. On the other hand, few results are available concerning effective thrombosis prophylaxis. In addition to the effectiveness, the pharmacokinetics of a substance and also possible bleeding complications must be taken into account. The parenteral administration of heparin and its short half life restrict it to use in thehospital. Oral anticoagulants, because they are difficult to dose, should be avoided when possible. Dextrans (Rheomacrodex) and acetylsalicylic acid (Colfarit) appear to be best suited for thrombosis prophylaxis in renal insufficiency. Dextran has the disadvantage of volume overload, and acetylsalicylic acid that of stomach intolerance. Sulfinpyrazone (Anturano) also appears to be effective, although its pharmacokinetic behaviour in renal insufficiency is still not known. Dipyridamole (Persantin), whose effectiveness for this purpose has not yet been demonstrate, should be administered even more cautiously.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 834017     DOI: 10.1007/BF01469082

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  68 in total

1.  COATING OF VASCULAR SURFACES AND CELLS. A NEW CONCEPT IN PREVENTION OF INTRAVASCULAR THROMBOSIS.

Authors:  W L BLOOM; D S HARMER; M F BRYANT; S S BREWER
Journal:  Proc Soc Exp Biol Med       Date:  1964-02

2.  THE RENAL CLEARANCE OF DEXTRAN OF DIFFERENT MOLECULAR SIZES IN NORMAL HUMANS.

Authors:  G ARTURSON; G WALLENIUS
Journal:  Scand J Clin Lab Invest       Date:  1964       Impact factor: 1.713

Review 3.  Drug selection and dosage in renal insufficiency.

Authors:  J Fabre; I Ohr
Journal:  Ergeb Inn Med Kinderheilkd       Date:  1974

4.  Controlled trial of dipyridamole in cerebral vascular disease.

Authors:  J Acheson; G Danta; E C Hutchinson
Journal:  Br Med J       Date:  1969-03-08

5.  Uraemic bleeding: a reversible platelet defect corrected by dialysis.

Authors:  J H Stewart; P A Castaldi
Journal:  Q J Med       Date:  1967-07

6.  [Chronic hemodialysis. Experience in 59 patients treated with 4614 hemodialyses].

Authors:  D Höffler; A Opitz; K Schaefer; H Knoop; O Knuth; E Quellhorst; H V Henning; F Scheler
Journal:  Arch Klin Med       Date:  1969

7.  Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy.

Authors:  H S Weily; E Genton
Journal:  Circulation       Date:  1970-11       Impact factor: 29.690

8.  [Peripheral subcutaneous arteriovenous shunts. Experiences with a new surgical technic].

Authors:  R de Pena Pérez; R Häring; S John; B Stallkamp; L C Tung; J Waldschmidt
Journal:  Med Welt       Date:  1971-04-17

9.  Reduction in venous thromboembolism by agents affecting platelet function.

Authors:  E W Salzman; W H Harris; R W DeSanctis
Journal:  N Engl J Med       Date:  1971-06-10       Impact factor: 91.245

10.  The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis.

Authors:  A Kaegi; G F Pineo; A Shimizu; H Trivedi; J Hirsh; M Gent
Journal:  Circulation       Date:  1975-09       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.